Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 22Other hematologic neoplasm 13Gastrointestinal 9Lymphoid 8Gynecologic 6Genitourinary 6CNS 6Tumor-Agnostic 5Thoracic 5Other solid neoplasm 5Head & Neck 5Plasma cell 4Dermatologic 4Sarcoma 3Other 2Myeloid 2Classical hematology 1

Conditions

Multiple Myeloma 4Renal Insufficiency 1Recurrence 1Peripheral Nervous System Diseases 1Neoplasms 1

Interventions

Dexamethasone 881Bortezomib 478Lenalidomide 467Cyclophosphamide 367Melphalan 275Calcium Dobesilate 264daratumumab 240pomalidomide 215carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 68Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 59Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Tablets × Plasma cell × Clear all
NCT07025005 2025-11-04

VRd MM Fibrate

Tanta University

Phase 4 Recruiting
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Peripheral Nervous System Diseases

NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting
50 enrolled
Plasma cell

Multiple Myeloma

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡